−2.1883USD
−118.51 MUSD
20.97 MUSD
46.46 M
About Cara Therapeutics, Inc.
Sector
Industry
CEO
Christopher A. Posner
Website
Headquarters
Stamford
Employees (FY)
55
Founded
2004
ISIN
US1407551092
FIGI
BBG001J2QYS9
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CARA is 0.71 USD — it has decreased by 7.08% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cara Therapeutics, Inc. stocks are traded under the ticker CARA.
Cara Therapeutics, Inc. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Cara Therapeutics, Inc. has a max estimate of 10.00 USD and a min estimate of 1.00 USD.
CARA earnings for the last quarter are −0.52 USD whereas the estimation was −0.52 USD which accounts for 0% surprise. Estimated earnings for the next quarter are −0.45 USD. See more details about Cara Therapeutics, Inc. earnings.
Cara Therapeutics, Inc. revenue for the last quarter amounts to 4.90 M USD despite the estimated figure of 9.95 M USD. In the next quarter revenue is expected to reach 9.42 M USD.
Yes, you can track Cara Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, CARA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cara Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 55.00 employees. See our rating of the largest employees — is Cara Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cara Therapeutics, Inc. EBITDA is −120.02 M USD, and current EBITDA margin is −578.20%. See more stats in Cara Therapeutics, Inc. financial statements.